Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0005116,
umls-concept:C0012000,
umls-concept:C0012373,
umls-concept:C0033497,
umls-concept:C0039155,
umls-concept:C0087111,
umls-concept:C0597198,
umls-concept:C0871261,
umls-concept:C1280500,
umls-concept:C1522565,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1707455,
umls-concept:C1874267,
umls-concept:C2911692
|
pubmed:issue |
11
|
pubmed:dateCreated |
1992-4-27
|
pubmed:abstractText |
Abnormalities of left ventricular (LV) systolic performance develop during exercise in patients with coronary artery disease (CAD) as a result of ischemia-induced regional wall motion abnormalities. Like patients with hypertension and those with hypertrophic cardiomyopathy, patients with CAD display abnormalities of LV diastolic performance under basal conditions in the absence of ischemia. The purpose of these studies was to compare the effects of bepridil versus those of propranolol or diltiazem in patients with exertional angina pectoris. LV systolic and diastolic performance were assessed at rest and during peak upright bicycle exercise by first-pass radionuclide ventriculography. Compared with propranolol, bepridil increased exercise capacity, cardiac output, and stroke volume and decreased systemic vascular resistance. Compared with diltiazem, bepridil increased exercise capacity, peak filling rate, and early diastolic filling fraction and decreased systemic vascular resistance, heart rate, time to peak filling rate, and atrial filling volume. Bepridil therapy is associated with improved exercise capacity and decreased anginal frequency and nitroglycerin consumption. In addition, its use is accompanied by favorable changes in LV systolic and diastolic function at rest and during exercise. These changes are consistent with benefits resulting from resolution of myocardial ischemia as well as from positive lusitropic effects of bepridil on the ventricular myocardium.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0002-9149
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
9
|
pubmed:volume |
69
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
25D-30D
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1553888-Angina Pectoris,
pubmed-meshheading:1553888-Bepridil,
pubmed-meshheading:1553888-Diastole,
pubmed-meshheading:1553888-Diltiazem,
pubmed-meshheading:1553888-Exercise Test,
pubmed-meshheading:1553888-Humans,
pubmed-meshheading:1553888-Propranolol,
pubmed-meshheading:1553888-Systole,
pubmed-meshheading:1553888-Vascular Resistance,
pubmed-meshheading:1553888-Ventricular Function, Left
|
pubmed:year |
1992
|
pubmed:articleTitle |
Effects of antianginal therapy on left ventricular systolic and diastolic performance: comparison of the response to bepridil, propranolol, and diltiazem.
|
pubmed:affiliation |
Division of Hypertension and Vascular Medicine, Massachusetts General Hospital, Boston 02114.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|